Karolinska Development AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.09.20	Karolinska Development's CFO is leaving the company (GlobeNewswire)
02.09.20	Karolinska Development’s portfolio company Umecrine Cognition presents results from clinical phase 2a study at AALSD International Liver Meeting (GlobeNewswire)
26.08.20	Promimic’s business partner launches unique 3D-printed implants following FDA approval (GlobeNewswire)
25.08.20	Karolinska Development’s Board director Magnus Persson resigns from his position (GlobeNewswire)
21.08.20	Karolinska Development's portfolio company OssDsign reports positive interim results from a study in patients with bone defects in the oral cavity (GlobeNewswire)
20.08.20	Karolinska Development’s Chairman of the Board resigns from his position (GlobeNewswire)
20.08.20	Interim Report - January-June 2020 (GlobeNewswire)
16.07.20	Karolinska Development’s portfolio company Aprea Therapeutics expands clinical trial of eprenetapopt for TP53 mutant Acute Myeloid Leukemia (GlobeNewswire)
08.07.20	Karolinska Development makes a partial sale of its holdings in the portfolio company Aprea Therapeutics and receives a net of SEK 39 million (GlobeNewswire)
15.06.20	Karolinska Development’s Annual General Meeting 2020 (GlobeNewswire)
12.06.20	Karolinska Development’s portfolio company Aprea Therapeutics presents positive results from a Phase 1b/2 study of APR-246 and azacitidine in MDS and AML (GlobeNewswire)
03.06.20	Karolinska Development’s portfolio company Aprea Therapeutics completes enrollment in Phase 3 study of eprenetapopt (GlobeNewswire)
01.06.20	Karolinska Development’s portfolio company OssDsign recruits Morten Henneveld as new Chief Executive Officer (GlobeNewswire)
01.06.20	Karolinska Development AB (publ) announces the Nomination Committee’s proposals and enables postal voting at the Annual General Meeting 2020 (GlobeNewswire)
18.05.20	Karolinska Development recruits John Öhd to the position of Chief Scientific Officer (GlobeNewswire)
11.05.20	Karolinska Development’ s portfolio company OssDsign granted full reimbursement for its implant product in Japan (GlobeNewswire)
08.05.20	Karolinska Development’s portfolio company Umecrine Cognition presents positive additional results from a phase 2a study of golexanolone (GlobeNewswire)
07.05.20	Notice of Annual General Meeting in Karolinska Development AB (publ) (GlobeNewswire)
30.04.20	Interim Report - January-March 2020 (GlobeNewswire)
17.04.20	Karolinska Development’s portfolio company Dilafor initiates collaboration with Liverpool University to study the effect of tafoxiparin on SARS-CoV-2 (GlobeNewswire)
13.04.20	Karolinska Development makes a partial sale of its holdings in the portfolio company Aprea Therapeutics and receives a net of SEK 59 million (GlobeNewswire)
03.04.20	Karolinska Development’s portfolio company Umecrine Cognition announces results from a phase 2a clinical study of golexanolone (GlobeNewswire)
30.03.20	Karolinska Development’s portfolio company OssDsign receives regulatory approval and prepares for launch in Japan (GlobeNewswire)
27.03.20	Karolinska Development invests in vaccine project to combat serious viral diseases (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Karolinska Development AB (B)

Aktien Top/Flop

Meistgelesene Nachrichten